Tag: commercialization
-
The space economy’s paradox — launch costs collapsed, but only one player won: SpaceX’s single vertically-integrated capture vs a thin downstream, and the series wrap-up
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All revenue, valuation and market-size figures are attributed to the filing, announcement or trade-press aggregate they come from; company claims, agency data, analyst estimates and press reports are separated inline. Marketed $/kg is…
-
Anatomy of the “synbio winter” — the tools/DNA-synthesis model survived, the platform/biomanufacturing model foundered, and whether the winter was a science failure or a business-model failure
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All revenues, margins, valuations, layoff rates and bankruptcy facts are attributed to each company’s own reporting (SEC 8-K/10-Q, corporate press releases) or the trade press; company claims, institutional statistics and market estimates are…
-
Quantum sensing, the commercial synthesis — the “most mature quantum quadrant” is real, but genuine field wins over the best classical sensor are narrow, and defense PNT demand is what actually pulls the market
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All funding, contract and valuation figures are attributed to each company’s press release, SEC filing (8-K / Form 425) or the trade press; company performance and “advantage” claims are kept separate from peer-reviewed…
-
In-vivo gene editing — big pharma bet on the delivery platform, not the editor, and the real bottleneck (hard outcomes) is untouched
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In 2025–26 big pharma bought its way into in-vivo gene editing and in-vivo CAR-T (Eli Lilly–Verve up to $1.3B; AbbVie–Capstan up to $2.1B). But the bet…
-
Bio Foundation Models: Where the Capital Is, Where the Evidence Isn’t, and Why the Two Point in Opposite Directions
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. Capital and reproducibility in biology’s foundation models flow in opposite directions: the largest raise sits behind the most closed engine (Isomorphic Labs, a $2.1B Series B in May 2026,…
-
The Real Bottleneck in AI Drug Discovery Is Biology: Where the Capital Is, Where the Clinic Isn’t, and Why They Point in Opposite Directions
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. Capital and clinical proof in AI drug discovery point in opposite directions. The best-financed pure-AI drug shops — Isomorphic Labs (a $2.1B Series B in May 2026), Xaira ($1B+…
Uthando Nethemba 